Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 115459625 | 11545962 | 5 | F | 20150822 | 20160913 | 20150924 | 20160926 | EXP | TH-TEVA-595594ISR | TEVA | 61.64 | YR | M | Y | 0.00000 | 20160926 | MD | TH | TH |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 115459625 | 11545962 | 1 | PS | WARFARIN | WARFARIN | 1 | Oral | 2.5 MILLIGRAM DAILY; | Y | 40145 | 2.5 | MG | TABLET | QD | |||||
| 115459625 | 11545962 | 2 | SS | WARFARIN | WARFARIN | 1 | Oral | 5 MILLIGRAM DAILY; | Y | 40145 | 2.5 | MG | TABLET | ||||||
| 115459625 | 11545962 | 3 | C | ASPIRIN. | ASPIRIN | 1 | Oral | 81 MILLIGRAM DAILY; CONTINUING | 0 | 81 | MG | QD | |||||||
| 115459625 | 11545962 | 4 | C | CLOPIDOGREL | CLOPIDOGREL BISULFATE | 1 | Oral | 75 MILLIGRAM DAILY; CONTINUING | 0 | 75 | MG | QD | |||||||
| 115459625 | 11545962 | 5 | C | CARATEN | 2 | Oral | 6.25 MILLIGRAM DAILY; CONTINUING | 0 | 6.25 | MG | QD | ||||||||
| 115459625 | 11545962 | 6 | C | LORSATAN | 2 | Oral | 50 MILLIGRAM DAILY; CONTINUING | 0 | 50 | MG | QD | ||||||||
| 115459625 | 11545962 | 7 | C | OMEPRAZOLE. | OMEPRAZOLE | 1 | Oral | 20 MILLIGRAM DAILY; | U | 0 | 20 | MG | QD | ||||||
| 115459625 | 11545962 | 8 | C | ATORVASTATIN | ATORVASTATIN | 1 | Oral | 40 MILLIGRAM DAILY; CONTINUING | 0 | 40 | MG | QD | |||||||
| 115459625 | 11545962 | 9 | C | Apolet | 2 | Oral | 75 MILLIGRAM DAILY; CONTINUING | 0 | 75 | MG | QD | ||||||||
| 115459625 | 11545962 | 10 | C | DIGOXIN. | DIGOXIN | 1 | Oral | .125 MILLIGRAM DAILY; CONTINUING | 0 | .125 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 115459625 | 11545962 | 1 | Atrial fibrillation |
| 115459625 | 11545962 | 3 | Coronary artery disease |
| 115459625 | 11545962 | 4 | Coronary artery disease |
| 115459625 | 11545962 | 5 | Coronary artery disease |
| 115459625 | 11545962 | 6 | Hypertension |
| 115459625 | 11545962 | 7 | Peptic ulcer |
| 115459625 | 11545962 | 8 | Dyslipidaemia |
| 115459625 | 11545962 | 9 | Coronary artery disease |
| 115459625 | 11545962 | 10 | Ischaemic cardiomyopathy |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 115459625 | 11545962 | LT |
| 115459625 | 11545962 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 115459625 | 11545962 | Atrial fibrillation | |
| 115459625 | 11545962 | Drug effect increased | Drug effect increased |
| 115459625 | 11545962 | Dyspnoea | |
| 115459625 | 11545962 | Septic shock | |
| 115459625 | 11545962 | Urinary tract infection |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 115459625 | 11545962 | 1 | 20150710 | 0 | ||
| 115459625 | 11545962 | 2 | 20150822 | 0 | ||
| 115459625 | 11545962 | 7 | 20150820 | 20150826 | 0 |